ATLASArbutus Biopharma (ABUS) earnings date: Nov 12, 2026
Arbutus Biopharma (ABUS) reports earnings for the quarter ended Sep 30, 2026 on Thu, Nov 12, 2026 (confirmed). Free email alerts for this report are just below.
Source: company filings and exchange data · Updated Nov 3, 2026
ATLAS view on ABUS
| Last price | $4.02 (+0.5%) |
|---|---|
| Normal 1-day range (±1σ) | ±2.4% |
| Earnings beat history | Beat the EPS estimate in 4 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Arbutus Biopharma stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Get an email before and after Arbutus Biopharma reports, free with your ATLAS account
Earnings alerts are a free benefit of your ATLAS account. The company goes to your watchlist and we email you when it reports. Google signup is one click.
Create free accountABUS earnings at a glance
| Next report (confirmed) | Thu, Nov 12, 2026 |
|---|---|
| Time | Not stated |
| Period | Quarter ended Sep 30, 2026 |
| Last report | Aug 12, 2026 · Miss |
| Beat rate (last 5 reports) | 4 of 5 (80%) |
| Average EPS surprise | +509.9% |
| Average move around a report | ±2.2% (last 5) |
| Sector | Healthcare · Biotechnology |
Arbutus Biopharma earnings history: last 5 reports
Arbutus Biopharma last reported on Aug 12, 2026: EPS of -$0.04 against an estimate of -$0.03 (-33.3% surprise), a miss.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 12, 2026 | -$0.03 | -$0.04 | -33.3% | Miss | -1.9% |
| May 13, 2026 | -$0.05 | $1.19 | +2,480.0% | Beat | +0.9% |
| Apr 29, 2026 | $3.69 | $4.10 | +11.1% | Beat | +1.2% |
| Mar 31, 2026 | $0.59 | $0.66 | +11.9% | Beat | +5.1% |
| Mar 23, 2026 | -$0.05 | -$0.01 | +80.0% | Beat | +1.7% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for ABUS
See the fair value, the probability range and the earnings history of Arbutus Biopharma on its ATLAS page.
Arbutus Biopharma (ABUS) stock analysisPlans from €3.99 a month.
Arbutus Biopharma earnings: frequently asked questions
When does Arbutus Biopharma (ABUS) report earnings?
Arbutus Biopharma is scheduled to report on Thursday, November 12, 2026 (the time of day has not been stated). ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
How often does ABUS beat earnings estimates?
Of its last 5 reports with a recorded result, Arbutus Biopharma beat the EPS estimate 4 times; the average surprise was +509.9%. Past results do not predict the next one.
How much does ABUS move around earnings?
Over its last 5 reports the stock moved an average of 2.2% (absolute, from the close before the report day to the close after it), and finished higher 4 of 5 times.
Did Arbutus Biopharma beat earnings estimates last quarter?
Arbutus Biopharma last reported on Aug 12, 2026: EPS of -$0.04 against an estimate of -$0.03 (-33.3% surprise), a miss.
How much does ABUS usually move in a day?
On a normal trading day the ATLAS model puts ABUS’s one-day range at about ±2.4%, with a 50% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Thu, Nov 12, 2026
Educational information, not investment advice. Disclaimer